Kerendia
Procedural steps taken and scientific information after the authorisation
Application number
Scope
Opinion/ 
Commission 
Product 
Summary
Notification1 
Decision 
Information 
issued on
Issued2 / 
affected3 
amended on
PSUSA/10978/202207
Periodic Safety Update EU Single 
09/02/2023
n/a
PRAC Recommendation - maintenance
assessment - finerenone
II/0001/G
This was an application for a group of 
15/12/2022
06/02/2023
SmPC and PL
Please refer to Scientific Discussion Kerendia-
variations.
H-C-5200-II-0001/G
C.I.13 - Other variations not specifically
covered elsewhere in this Annex which
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures.
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000
An agency of the European Union
involve the submission of studies to the 
competent authority
C.I.6.a - Change(s) to therapeutic 
indication(s) - Addition of a new therapeutic 
indication or modification of an approved 
one
C.I.4 - Change(s) in the SPC, Labelling or PL 
due to new quality, preclinical, clinical or 
pharmacovigilance data
Page 2/2
